Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ning Xu, PhD, Nicole Ng, BS, Mingjie Li, BS, Erin Yu, BS, Eric Sanchez, BA, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1824.

https://doi.org/10.1182/blood-2019-131047

Published: 2019

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

Journal Articles

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

Scott Kristian Jew, BS, Tiffany Chang, BS, Sean Elliott Bujarski, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Tahmineh Safaie, Mingjie Li, BS, Eric Sanchez, BA, Cathy S. Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4393.

https://doi.org/10.1182/blood-2019-132013

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

James R Berenson, MD, To Jennifer, BS, Tanya M. Spektor, PhD, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Alberto Bessudo, MD, Ravindranath Patel, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2018) 132 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2018-99-119274

Published: 2018

Journal Articles

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia M. Soof, BS, Sean Bujarski, BA, Nicole Ng, Jasmin Cao, BS, Tara Hekmati, BS, Edward J Tanenbaum, BS, Brian Zahab, Cathy S. Wang, BS, George Y Tang, PhD, Ning Xu, PhD, James R Berenson, MD

Blood (2018) 132 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2018-99-119099

Published: 2018

Journal Articles

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Sean Bujarski, BA, Camilia Soof, BS, Mingjie Li, BS, Cathy S. Wang, BS, Eric Sanchez, BA, Marsiye Emamy-Sadr, Regina Swift, Kian Rahbari, Saurabh Patil, BS, Tanya M. Spektor, PhD, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2018) 132 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2018-99-119190

Published: 2018

Journal Articles

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clare Sun, MD, Camilia Soof, BS, Alankrita Taneja, MD, Sarah E. M. Herman, PhD, Erika Cook, BA, Kyle Udd, BA, Haiming Chen, MD PhD, Eric Sanchez, BA, Xin Tian, PhD, Inhye E. Ahn, MD, James R Berenson, MD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4031.

https://doi.org/10.1182/blood.V130.Suppl_1.4031.4031

Published: 2017

Journal Articles

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia Soof, BS, Saurabh Patil, BS, Kyle Udd, BA, Mizi Zhou, MS, Tara Hekmati, BS, Emily Y Wang, Edward J Tanenbaum, BS, Remy Schlossberg, Moryel A Yashar, BS, Cathy S Wang, BS, George Y Tang, PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4413.

https://doi.org/10.1182/blood.V130.Suppl_1.4413.4413

Published: 2017

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4371.

https://doi.org/10.1182/blood.V130.Suppl_1.4371.4371

Published: 2017

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Eric Sanchez, BA, Mingjie Li, BS, Cathy S Wang, BS, Edward J Tanenbaum, BS, Saurabh Patil, BS, Camilia Soof, BS, Tara Hekmati, BS, Remy E Schlossberg, BS, Moryel A Yashar, BS, Autumn L Porter, BS, George Y Tang, PhD, Haiming Chen, MD PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 5393.

https://doi.org/10.1182/blood.V130.Suppl_1.5393.5393

Published: 2017

Journal Articles

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

Blood (2017) 130 (Supplement 1): 5390.

https://doi.org/10.1182/blood.V130.Suppl_1.5390.5390

Published: 2017

Journal Articles

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson, MD

Blood (2016) 128 (22): 3325.

https://doi.org/10.1182/blood.V128.22.3325.3325

Published: 2016

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Kyle Udd, BA, Haiming Chen, MD PhD, Mingjie Li, BS, Camilia M Soof, BS, Christian Casas, BS, Soudabeh Etessami, PhD, Zachary Gross, MD, Matthew Ghermezi, James Wang, Eric Sanchez, BA, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5654.

https://doi.org/10.1182/blood.V128.22.5654.5654

Published: 2016

Journal Articles

Gene Expression of Gamma Secretase (GS) Complex-Related Proteins, the Enzyme That Sheds B-Cell Maturation Antigen (BCMA), Among Patients with Multiple Myeloma (MM) and Effects of the GS Inhibitor LSN424354 on Solubilized Bcma in MM and Chronic Lymphocytic Leukemia

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Cathy S Wang, BS, Kyle A Udd, BA, Camilia M Soof, BS, Christian E Casas, BS, Jessica Wang, MS, Jasmin Cao, Kevin DeCorso, Tara Hekmati, George Tang, PhD, James R. Berenson, MD

Blood (2016) 128 (22): 5641.

https://doi.org/10.1182/blood.V128.22.5641.5641

Published: 2016

NARROW

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Gene Expression of Gamma Secretase (GS) Complex-Related Proteins, the Enzyme That Sheds B-Cell Maturation Antigen (BCMA), Among Patients with Multiple Myeloma (MM) and Effects of the GS Inhibitor LSN424354 on Solubilized Bcma in MM and Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only